Contrariwise, Lin et al. [21] suggested that FOXO3 overexpression could ameliorate n6-methyladenosine-related sorafenib sensitivity in HCC by autophagy inhibition under hypoxia. The gene discussed is FOXO3; the disease is hepatocellular carcinoma.